Related Experiment Video
Updated: Aug 9, 2026
05:55
Delivery of Therapeutic Agents Through Intracerebroventricular (ICV) and Intravenous (IV) Injection in Mice
Published on: October 3, 2011
Spinal muscular atrophy type 1: management and outcomes
John R Bach1, J Scott Baird, Daniel Plosky
1Department of Physical Medicine and Rehabilitation, UMDNJ-New Jersey Medical School, Newark, New Jersey 07103, USA. bachjr@umdnj.edu
Pediatric Pulmonology
|July 12, 2002
Summary
Spinal muscular atrophy type 1 (SMA1) patients benefit from respiratory support. Noninvasive ventilation offers better long-term outcomes, including speech and fewer hospitalizations, compared to tracheostomy.
Area of Science:
- Pediatric Neurology
- Pulmonology
- Genetics
Background:
- Spinal muscular atrophy type 1 (SMA1) is a severe genetic neuromuscular disorder characterized by progressive muscle weakness and respiratory failure.
- Respiratory support is crucial for survival in SMA1 patients, with options including tracheostomy ventilation and noninvasive ventilation.
- Understanding the long-term outcomes of different ventilation strategies is essential for optimizing patient care.
Purpose of the Study:
- To compare survival, hospitalization rates, speech capabilities, and overall outcomes in SMA1 patients receiving noninvasive ventilation versus tracheostomy.
- To evaluate the impact of respiratory support methods on the quality of life and functional abilities of children with SMA1.
Main Methods:
- Retrospective analysis of 56 SMA1 patients who developed respiratory failure before age 2.
- Patients were divided into two groups: Group A (tracheostomy ventilation) and Group B (noninvasive ventilation with assisted coughing).
- Data collected included age at intervention, survival duration, hospitalization frequency, and communication abilities.
Main Results:
- Tracheostomy (Group A) was associated with fewer hospitalizations until age 3 but more after age 5 compared to noninvasive ventilation (Group B).
- Most tracheostomy patients (15/16) lost spontaneous breathing and speech ability, whereas noninvasive ventilation allowed for speech in most patients.
- Noninvasive ventilation patients experienced longer survival and better functional outcomes, with 3 requiring continuous high-level support and 4 unable to communicate verbally.
Conclusions:
- SMA1 children can achieve long-term survival with either tracheostomy or noninvasive respiratory support.
- Noninvasive ventilation is linked to reduced hospitalizations after age 5, freedom from daytime ventilator dependence, and preserved speech.
- Noninvasive ventilation appears to be a superior strategy for improving functional outcomes and quality of life in SMA1 patients.
More Related Videos
10:49Intraspinal Cell Transplantation for Targeting Cervical Ventral Horn in Amyotrophic Lateral Sclerosis and Traumatic Spinal Cord Injury
Published on: September 18, 2011
12:35Clinical Testing and Spinal Cord Removal in a Mouse Model for Amyotrophic Lateral Sclerosis (ALS)
Published on: March 17, 2012
Related Concept Videos
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:15Myasthenia Gravis: Diagnostic Tests
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
01:31Skeletal Muscle Relaxants: Therapeutic Uses
Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx as...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:11Alterations in Muscle Tone lll
Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...